A citation-based method for searching scientific literature

Ramar Vanajothi, Hemamalini Vedagiri, Mysoon M Al-Ansari, Latifah A Al-Humaid, Premkumar Kumpati. J Biomol Struct Dyn 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto. Transl Lung Cancer Res 2015
144
100

SwissParam: a fast force field generation tool for small organic molecules.
Vincent Zoete, Michel A Cuendet, Aurélien Grosdidier, Olivier Michielin. J Comput Chem 2011
811
100

Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Assunta Sgambato, Francesca Casaluce, Paolo Maione, Cesare Gridelli. Expert Rev Anticancer Ther 2018
56
100

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
100

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
Mingxiang Ye, Xinxin Zhang, Nan Li, Yong Zhang, Pengyu Jing, Ning Chang, Jianxiong Wu, Xinling Ren, Jian Zhang. Oncotarget 2016
20
100

VMD: visual molecular dynamics.
W Humphrey, A Dalke, K Schulten. J Mol Graph 1996
100

Pharmacotherapeutics and Molecular Mechanism of Phytochemicals in Alleviating Hormone-Responsive Breast Cancer.
Shailima Rampogu, Chanin Park, Doneti Ravinder, Minky Son, Ayoung Baek, Amir Zeb, Rohit Bavi, Raj Kumar, Gihwan Lee, Shraddha Parate,[...]. Oxid Med Cell Longev 2019
6
100

Dietary flavonoid intake and lung cancer--a population-based case-control study.
Yan Cui, Hal Morgenstern, Sander Greenland, Donald P Tashkin, Jenny T Mao, Lin Cai, Wendy Cozen, Thomas M Mack, Qing-Yi Lu, Zuo-Feng Zhang. Cancer 2008
91
100


g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations.
Rashmi Kumari, Rajendra Kumar, Andrew Lynn. J Chem Inf Model 2014
100


Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice.
Amit S Choudhari, Pallavi C Mandave, Manasi Deshpande, Prabhakar Ranjekar, Om Prakash. Front Pharmacol 2020
151
100

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
159
100

Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
Disha Pathak, Navriti Chadha, Om Silakari. J Mol Graph Model 2016
11
100

Improved protein-ligand docking using GOLD.
Marcel L Verdonk, Jason C Cole, Michael J Hartshorn, Christopher W Murray, Richard D Taylor. Proteins 2003
100

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
132
100

Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Mark M Awad, Ryohei Katayama, Michele McTigue, Wei Liu, Ya-Li Deng, Alexei Brooun, Luc Friboulet, Donghui Huang, Matthew D Falk, Sergei Timofeevski,[...]. N Engl J Med 2013
242
100

Development and validation of a genetic algorithm for flexible docking.
G Jones, P Willett, R C Glen, A R Leach, R Taylor. J Mol Biol 1997
100

Scutellaria Flavonoids Effectively Inhibit the Malignant Phenotypes of Non-small Cell Lung Cancer in an Id1-dependent Manner.
Zhengxiao Zhao, Baojun Liu, Jing Sun, Linwei Lu, Lumei Liu, Jian Qiu, Qiuping Li, Chen Yan, Shan Jiang, Nabijan Mohammadtursun,[...]. Int J Biol Sci 2019
16
100

Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids.
Qingmei Ye, Kai Liu, Qun Shen, Qingyue Li, Jinghui Hao, Fangxuan Han, Ren-Wang Jiang. Front Oncol 2019
54
100

Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC.
Disha Pathak, Shalki Choudhary, Pankaj Kumar Singh, Manjinder Singh, Navriti Chadha, Om Silakari. Mol Divers 2021
3
100

Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
Yuanxin Tian, Yonghuan Yu, Yudong Shen, Hua Wan, Shan Chang, Tingting Zhang, Shanhe Wan, Jiajie Zhang. J Chem Inf Model 2017
10
100

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Julian R Molina, Ping Yang, Stephen D Cassivi, Steven E Schild, Alex A Adjei. Mayo Clin Proc 2008
100

Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling.
Jamel Meslamani, Jiabo Li, Jon Sutter, Adrian Stevens, Hugues-Olivier Bertrand, Didier Rognan. J Chem Inf Model 2012
73
100

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Monika A Davare, Nadeem A Vellore, Jacob P Wagner, Christopher A Eide, James R Goodman, Alexander Drilon, Michael W Deininger, Thomas O'Hare, Brian J Druker. Proc Natl Acad Sci U S A 2015
67
100

Progress in Research on the Role of Flavonoids in Lung Cancer.
Oana Zanoaga, Cornelia Braicu, Ancuta Jurj, Alexandru Rusu, Rares Buiga, Ioana Berindan-Neagoe. Int J Mol Sci 2019
19
100

Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies.
Shailima Rampogu, Shraddha Parate, Saravanan Parameswaran, Chanin Park, Ayoung Baek, Minky Son, Yohan Park, Seok Ju Park, Keun Woo Lee. Comput Biol Chem 2019
14
100


Recent Developments and Applications of the CHARMM force fields.
Xiao Zhu, Pedro E M Lopes, Alexander D Mackerell. Wiley Interdiscip Rev Comput Mol Sci 2012
170
100

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
15
100

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
Alexander Drilon, Romel Somwar, Jacob P Wagner, Nadeem A Vellore, Christopher A Eide, Matthew S Zabriskie, Maria E Arcila, Jaclyn F Hechtman, Lu Wang, Roger S Smith,[...]. Clin Cancer Res 2016
101
100


Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
Dickran Kazandjian, Gideon M Blumenthal, Lola Luo, Kun He, Ingrid Fran, Steven Lemery, Richard Pazdur. Oncologist 2016
51
100

Myricetin: versatile plant based flavonoid for cancer treatment by inducing cell cycle arrest and ROS-reliant mitochondria-facilitated apoptosis in A549 lung cancer cells and in silico prediction.
Padmini Rajendran, Uma Maheshwari, Arun Muthukrishnan, Razia Muthuswamy, Krishnan Anand, Balasubramani Ravindran, Premnath Dhanaraj, Balasubramaninan Balamuralikrishnan, Soon Woong Chang, Woo Jin Chung. Mol Cell Biochem 2021
8
100

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.
Viola Weijia Zhu, Daya Upadhyay, Alexa B Schrock, Kyle Gowen, Siraj M Ali, Sai-Hong Ignatius Ou. Lung Cancer 2016
27
100

Pharmacophore modeling in drug discovery and development: an overview.
Santosh A Khedkar, Alpeshkumar K Malde, Evans C Coutinho, Sudha Srivastava. Med Chem 2007
71
100

Total flavonoids suppress lung cancer growth via the COX-2-mediated Wnt/β-catenin signaling pathway.
Lei Han, Shu Fang, Guangtao Li, Minghuan Wang, Renzhi Yu. Oncol Lett 2020
4
100

Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
Yuanxin Tian, Tingting Zhang, Lifan Long, Zhonghuang Li, Shanhe Wan, Guangfa Wang, Yonghuan Yu, Ju Hou, Xiaoyun Wu, Jiajie Zhang. Eur J Med Chem 2018
7
100

Molecular mechanism and pharmacokinetics of flavonoids in the treatment of resistant EGF receptor-mutated non-small-cell lung cancer: A narrative review.
Xuewen Wang, Bing Chen, Dafen Xu, Zhijun Li, Hao Liu, Zhengjun Huang, Kangping Huang, Xinhua Lin, Hong Yao. Br J Pharmacol 2021
4
100

Novel method for generating structure-based pharmacophores using energetic analysis.
Noeris K Salam, Roberto Nuti, Woody Sherman. J Chem Inf Model 2009
195
100


Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.
Swapnil Rajurkar, Isa Mambetsariev, Rebecca Pharaon, Benjamin Leach, TingTing Tan, Prakash Kulkarni, Ravi Salgia. J Clin Med 2020
9
100

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
Lian-Xiang Luo, Xing-Xing Fan, Ying Li, Xia Peng, Yin-Chun Ji, Wendy Wen-Luan Hsiao, Liang Liu, Elaine Lai-Han Leung, Xiao-Jun Yao. Medchemcomm 2017
3
100

New features that improve the pharmacophore tools from Accelrys.
Jon Sutter, Jiabo Li, Allister J Maynard, Anne Goupil, Tien Luu, Katalin Nadassy. Curr Comput Aided Drug Des 2011
20
100

Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
Raj Kumar, Saravanan Parameswaran, Rohit Bavi, Ayoung Baek, Minky Son, Shailima Rampogu, Chanin Park, Gihwan Lee, Amir Zeb, Shraddha Parate,[...]. J Mol Graph Model 2019
9
100

Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics.
Shraddha Parate, Vikas Kumar, Gihwan Lee, Shailima Rampogu, Jong Chan Hong, Keun Woo Lee. Pharmaceuticals (Basel) 2021
7
100

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Lukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando López-Ríos, Antonio Marchetti, Büge Öz, Patrick Pauwels,[...]. Virchows Arch 2016
131
100

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells. PLoS One 2020
26
100

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
Monika A Davare, Anna Saborowski, Christopher A Eide, Cristina Tognon, Rebecca L Smith, Johannes Elferich, Anupriya Agarwal, Jeffrey W Tyner, Ujwal P Shinde, Scott W Lowe,[...]. Proc Natl Acad Sci U S A 2013
84
100

Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
Ling Shan, Fang Lian, Lei Guo, Tian Qiu, Yun Ling, Jianming Ying, Dongmei Lin. PLoS One 2015
66
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.